CORONA, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that its subsidiary Watson Laboratories, Inc. has reached a settlement with Barr Laboratories, Inc. on outstanding patent litigation related to Watson’s Oxytrol(R) (Oxybutynin Transdermal System, 3.9mg/24hr.) product.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).
(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)
Photo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO
http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.comWatson Pharmaceuticals, Inc.
